* ARCUTIS PRESENTS LATE-BREAKING DATA FROM THE INTEGUMENT
PHASE 3
TRIALS IN ATOPIC DERMATITIS AT AMERICAN ACADEMY OF DERMATOLOGY
ANNUAL MEETING
* ARCUTIS – NEW INTEGUMENT-1, INTEGUMENT-2 DATA SHOW RAPID,
SIGNIFICANT REDUCTION IN ITCH AS EARLY AS 24 HOURS AFTER FIRST
APPLICATION OF ROFLUMILAST CREAM 0.15%
* ARCUTIS BIOTHERAPEUTICS – INCIDENCES OF ADVERSE EVENTS
WERE LOW,
WITH NO ADVERSE EVENT OCCURRING IN MORE THAN 3.5% OF SUBJECTS IN
EITHER ARM
* ARCUTIS – IN BOTH STUDIES, ROFLUMILAST CREAM IMPROVED
ATOPIC
DERMATITIS ACROSS MULTIPLE EFFICACY ENDPOINTS DEMONSTRATING
FAVORABLE SAFETY, TOLERABILITY
Source text for Eikon:
Further company coverage:
Read more here: Source link
